Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBW-3210 in Chinese Patients with Mature B-cell Lymphoma (Phase I/II)
ChiCTR2400089717Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HBW-3210 in B-cell non-Hodgkin lymphoma (B-NHL), primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL) and 7 more (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Maximum tolerated dose (MTD), Dose-limiting toxicity (DLT) and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
HBW-3210
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2400089717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089717.